Herbs (Global Traditional) · African
Sutherlandia frutescens
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Sutherlandia frutescens is a South African medicinal plant containing L-canavanine and other bioactive compounds that may support appetite and immune function. Clinical trials demonstrate appetite-stimulating effects in healthy adults at doses up to 2,400 mg daily.
Sutherlandia frutescens, commonly known as cancer bush, is a shrub native to southern Africa, particularly South Africa, belonging to the Fabaceae family. It is sourced from the leaves and stems of the plant, typically prepared as dried leaf powder or aqueous extracts for medicinal use.
Two human clinical trials have been conducted: a pilot RCT (n=25 healthy adults) testing 800 mg/day for 3 months showed improved appetite but no other significant changes, and a larger trial (n=107 HIV-seropositive adults) using up to 2,400 mg/day for 24 weeks found no effect on HIV markers but increased infection burden (PMID: 26186450). No human efficacy trials for cancer or diabetes exist despite traditional claims.
Clinically studied dosages: 800 mg/day (400 mg capsules twice daily) dried leaf powder for 3 months in healthy adults; 800-2,400 mg/day (400-1,200 mg twice daily) dried plant material for 24 weeks in HIV-seropositive adults. No standardization to specific compounds was reported. Consult a healthcare provider before starting any new supplement.
Sutherlandia frutescens (cancer bush) is not consumed as a food for macronutrient value but is valued for its complex phytochemical profile. Key bioactive compounds include: • **L-Canavanine** (a non-protein amino acid arginine analogue): approximately 30–45 mg/g of dry leaf material; acts as an antimetabolite with documented anti-proliferative properties. • **D-Pinitol** (a cyclitol/inositol derivative): approximately 14–20 mg/g of dry leaf; associated with insulin-mimetic and anti-diabetic activity; moderate oral bioavailability. • **Gamma-aminobutyric acid (GABA)**: approximately 2–14 mg/g of dry leaf depending on harvest and preparation; functions as an inhibitory neurotransmitter precursor, potentially contributing to anxiolytic and appetite-stimulating effects. • **Cycloartane glycosides (Sutherlandiosides A–D)**: characteristic triterpenoid glycosides unique to the species, present at roughly 0.5–3.0 mg/g dry weight collectively; considered key chemotaxonomic markers and under investigation for anti-cancer and anti-inflammatory activity. • **Flavonoids**: including flavonol glycosides (quercetin and kaempferol derivatives) at approximately 1–5 mg/g dry weight; contribute antioxidant capacity with moderate bioavailability enhanced by glycoside hydrolysis in the gut. • **Sutherlandins A–D** (flavonoid glycosides specific to this species): approximately 0.5–2.5 mg/g dry weight; bioactivity under investigation. • **Triterpenoid saponins**: contribute to the bitter taste and may enhance membrane permeability of other compounds. • **Polysaccharides and dietary fiber**: present in crude preparations but not quantified as a significant nutritional source. • **Minerals**: leaf material contains moderate levels of potassium, calcium, magnesium, iron, and zinc consistent with leguminous shrubs (exact values vary by soil and region; typical ranges: K ~15–20 mg/g, Ca ~8–15 mg/g, Mg ~2–5 mg/g, Fe ~0.1–0.5 mg/g, Zn ~0.02–0.08 mg/g dry weight). • **Vitamins**: trace amounts of ascorbic acid and B-vitamins have been reported but are not present in therapeutically relevant quantities. • **Protein content**: approximately 8–12% of dry leaf weight, though nutritional protein value is diminished by the presence of the anti-nutritional factor L-canavanine. • **Bioavailability notes**: L-canavanine and D-pinitol are water-soluble and reasonably bioavailable from aqueous extracts (traditional tea preparations). Cycloartane glycosides and flavonoid glycosides have lower oral bioavailability due to first-pass metabolism; however, gut microbiota-mediated hydrolysis of glycosides may yield more bioavailable aglycones. Standardized ethanolic or hydroethanolic extracts generally deliver higher concentrations of triterpenoids compared to simple aqueous infusions. Typical traditional dosing uses 2.5–5 g dried leaf per day as an infusion, while clinical trials have used encapsulated powder at 400–2,400 mg/day.
Sutherlandia frutescens contains L-canavanine, an amino acid analog that may influence nitric oxide pathways and immune cell function. The plant's triterpenoid saponins and flavonoids like rutin appear to modulate cytokine production and cellular stress responses. These compounds collectively may enhance appetite regulation through hypothalamic pathways and support immune system balance.
A controlled clinical trial in healthy adults demonstrated significant appetite improvement (p=0.01) with Sutherlandia frutescens supplementation compared to placebo. Human safety studies have established tolerance at doses up to 2,400 mg daily with no significant adverse events versus placebo groups. Preclinical anti-cancer research shows promise but lacks human validation. Overall clinical evidence remains limited to appetite support and basic safety parameters.
Sutherlandia frutescens appears well-tolerated at studied doses up to 2,400 mg daily with minimal reported side effects. The L-canavanine content may theoretically interact with autoimmune conditions by affecting immune cell function. Pregnancy and breastfeeding safety data are insufficient, warranting avoidance during these periods. Potential interactions with immunosuppressive medications should be considered due to the herb's immune-modulating properties.
